Looking back at cancer drugs: do they hold up in the real world?
NCT ID NCT07024680
Summary
This study aims to understand how effective and safe two existing cancer drugs, sunitinib and sorafenib, are for Chinese adults with advanced papillary kidney cancer that cannot be surgically removed. Researchers will look back at the medical records of about 150 patients who received one of these drugs as their first treatment. The goal is to see how long the drugs helped control the cancer in everyday hospital settings, rather than in a controlled clinical trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAPILLARY RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.